Apyx Medical Corp (APYX)
Health Care · surgical aesthetics / medical devices · NASDAQ
A surgical aesthetics company specializing in helium plasma-based body contouring and tissue tightening solutions for cosmetic and hospital procedures.
What Apyx Medical Corp does
Apyx Medical is a surgical aesthetics company that develops and markets the Helium Plasma Platform Technology, including the Renuvion and AYON body contouring systems. The company's products are used by surgeons for various procedures, including fat removal, tissue contraction, and skin laxity treatment, in both cosmetic and hospital settings. Additionally, Apyx Medical leverages its expertise in unique waveforms through OEM manufacturing contracts with other medical device companies.
Recent developments
In the second quarter of 2026, the company reported 28% growth in its Surgical Aesthetics segment, driven by the AYON platform, and reaffirmed its full-year 2026 revenue guidance of $59.0 million to $60.0 million. The company also commenced a limited commercial launch of its power liposuction handpiece for the AYON system in June 2026.
From Apyx Medical Corp's filing of 2026-08-06.
Themes: surgical aesthetics, body contouring, tissue tightening, helium plasma technology, electrosurgery, medical device manufacturing, OEM services
Fundamentals
- Price$2.44 as of 2026-10-20 close
- Market cap$103M as of 2026-08-05 (share count; price 2026-10-20)
- 1-year return-22.0% 2025-10-20 close $3.13 → 2026-10-20 close $2.44
- P/En/a negative earnings
- Net margin-21.2% FY2025, SEC XBRL
- Gross margin+62.5% FY2025, SEC XBRL
- ROE-77.1% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity3.31 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+9.9% FY2025, SEC XBRL
- Revenue CAGR (3y)+5.9% SEC XBRL
- Beta1.50 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How APYX compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $14M | $9M | -$2M | -$3M | -$3M† | $66000† |
| Q1 FY2026 2026-03-31 | $12M | $8M | -$911000 | -$2M | -$572000 | $60000 |
| Q4 FY2025 2025-12-31 | $19M† | $12M† | $11000† | -$1M† | -$3M† | $275000† |
| Q3 FY2025 2025-09-30 | $13M | $8M | -$832000 | -$2M | -$4M† | $519000† |
| Q2 FY2025 2025-06-30 | $11M | $7M | -$3M | -$4M | -$1M† | $265000† |
| Q1 FY2025 2025-03-31 | $9M | $6M | -$3M | -$4M | -$702000 | $55000 |
| Q4 FY2024 2024-12-31 | $14M† | $9M† | -$3M† | -$5M† | -$3M† | $245000† |
| Q3 FY2024 2024-09-30 | $11M | $7M | -$4M | -$5M | -$4M† | $153000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$28M
- Total debt$35M borrowings only; leases excluded
- Net debt$8M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Apyx Medical Corp looks technically
Apyx Medical Corp (APYX) is trading 32.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 34 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive). It made a new 20-day low about 9 trading days ago. It is 51.1% below its highest point of the past year. Trading volume is running unusually high — about 2.5× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 32.8% below its 200-day average, the long-term trend line — a long-term downtrend | -32.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.86 | $2.86 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.63 | $3.63 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes above 2.73. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 34 trading days ago — a "death cross", a bearish long-term signal | 34 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with sellers in control | 36.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30) | 37.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($2.34 to $2.73) — its "stochastic" reading is 26 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 25.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.99 | $4.99 |
|---|---|---|
| From the 52-week high | it is 51.1% below its 52-week high (its highest price of the past year) | -51.1% |
| Above the 52-week low | it is 5.2% above its 52-week low (its lowest price of the past year) | +5.2% |
| Below the 52-week high | it is 51.1% below its highest point of the past year | 51.1% |
| Since a 20-day breakout | it made a new 20-day low about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day low about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $17.49 (set on 2021-11-22) | $17.49 |
| Given back of the 52-week move | over the past year its closes ranged ($2.36 to $4.77), and it has recovered only a small part of its fall from last year’s high — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.85 to $3.93. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.3% |
| From the all-time high | it is 86.0% below its all-time high | -86.0% |
| Nearest price level | it is trading 4.6% above a support level at $2.33 — a price it turned at four times since 2025-06-24, most recently on 2026-10-08. Since 2024-10-21 it has 6 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.6% |
| All-time low | its lowest closing price on record is $0.7554 (set on 2025-04-04) | $0.7554 |
| Above the all-time low | it is 223.0% above its all-time low | +223.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 41st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1751 between its high and its low — about 7.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1751 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.28 and $2.90 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.28 – $2.59 – $2.90 |
| Typical daily range (% of price) | its price moves about 7.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.2% |
| Stretch from the 200-day average | it is trading 6.8 daily ranges below its 200-day average price (32.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.5× its 30-day average, a sign of heightened interest | 2.53× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.2% |
|---|---|---|
| Open gap | it gapped 2.0% below the previous close 16 sessions ago and has not traded back through the level it left behind at 2.96 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.0% |
| Gap filled | a 4.7% gap down opened on 2026-10-15 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 3 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 21.2 percentage points (the stock lost 20.3% while the market gained 1.0%) | -21.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 43.7 percentage points (the stock lost 40.0% while the market gained 3.6%) | -43.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 46.6 percentage points (the stock lost 38.1% while the market gained 8.5%) | -46.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 36.6 percentage points (the stock lost 22.0% while the market gained 14.6%) | -36.6% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 25% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 24.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -24.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 32% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.59 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | -32.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 15% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.87 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | -15.0% |
Price levels it has turned at before
APYX last closed at $2.44 on 2026-10-20. Since 2024-10-21 it has turned at 6 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.33 | Support | 4.6% below the last close | turned there four times · 2025-06-24 to 2026-10-08 |
| $2.73 | Resistance | 11.9% above the last close | turned there four times · 2025-07-07 to 2026-10-12 |
| $2.81 | Resistance | 15.4% above the last close | turned there three times · 2025-10-30 to 2026-09-11 |
| $1.81 | Support | 25.8% below the last close | turned there four times · 2024-12-24 to 2025-09-03 |
| $1.76 | Support | 27.7% below the last close | turned there twice · 2025-05-13 to 2025-05-28 |
| $3.28 | Resistance | 34.4% above the last close | turned there twice · 2025-10-24 to 2026-08-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes above $2.73.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $1.92 and $2.42 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 2 trading days, since 2026-10-19.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Unusually heavy trading volume · lagging the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$6.50 range $6.00 – $8.00; median $6.00
Analyst estimates, as of 2026-10-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for APYX
- Consensus EPS estimate-$0.09333 next reporting period, as of 2026-10-19
- Estimate change, 30 days+$0.00267 from -$0.096, on 2026-09-15, 34-day window
- Readings revised upward10% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Recurring net losses and history of cash outflows from operations create uncertainty regarding future liquidity and capital needs.","Substantial dependence on OEM customers who are under no legal obligation to purchase products.","Potential for ongoing or future compliance challenges with debt covenants if revenue or expense targets are not met."]
What changed in the latest 10-Q
AI-assisted comparison of APYX's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-06) states that on May 11, 2026, the company announced it received expanded 510(k) clearance from the FDA for the AYON Body Contouring System to include power liposuction, and that the company commenced a limited commercial launch of power liposuction at the end of June 2026.
- Newer filing (2026-08-06) adds an 'Operating Segments' heading before the paragraph about operating segments.
- Removed:
- Older filing (2026-05-07) states that on October 13, 2025, the company announced it had submitted the 510(k) premarket notification to the FDA for the label expansion of AYON to include power liposuction, and that the company anticipated receiving clearance in the second quarter of 2026.
- Reworded:
- The newer filing dated 2026-08-06 references the Annual Report on Form 10-K filed with the SEC on March 10, 2026; the older filing dated 2026-05-07 references the Annual Report on Form 10-K filed with the SEC on March 13, 2025.
- Handpiece unit sales figure changed: newer filing (2026-08-06) reports approximately 48,000 units sold in the six months ended June 30, 2026 and approximately 40,000 units in the six months ended June 30, 2025; older filing (2026-05-07) reports approximately 26,000 units sold in the three months ended March 31, 2026 and approximately 19,000 units in the three months ended March 31, 2025.
- Newer filing (2026-08-06) says 'In the U.S., handpiece revenue accounts for more than 50%'; older filing (2026-05-07) says 'In the U.S. Handpiece revenue accounts for more than 50%' (punctuation difference: period vs. comma after 'U.S.').
- Newer filing (2026-08-06) uses 'GLP-1s' with closing double quote in '("GLP-1s")'; older filing (2026-05-07) uses standard double quote characters in '("GLP-1s")' (minor punctuation/quote style difference).
- Notes:
- The newer MD&A text appears truncated mid-sentence in the 'Operating Segments' paragraph ('the manage...') and the older text ends with 'Asset informati'; full end of section not available in either excerpt, so changes after that point cannot be assessed.
Risk Factors
- Added:
- Newer filing (filed 2026-08-06) added Exhibit 10.1, a Letter Agreement between Company and Stavros Vizirgianakis, dated June 11, 2026 (Incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on June 17, 2026).
- Reworded:
- Signature dates changed from May 7, 2026 (older filing filed 2026-05-07) to August 6, 2026 (newer filing filed 2026-08-06).
- Notes:
- No changes to the Risk Factors section text itself; the Risk Factors text is identical in both filings.
- Text supplied includes sections beyond Risk Factors (Items 2-6, Signatures); comparison reflects differences in the full supplied texts.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for APYX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding APYX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 1,572,158
- Reported value $7,058,989
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about APYX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
APYX had 206,825 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
APYX had 0.49% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.17 days to cover at the same settlement.
- Reported short interest (shares) 206,825
- Short interest (% of shares outstanding) 0.49%
- Prior settlement (shares) 218,049
- Reported change -5.15%
- Days to cover (reported) 1.17
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- InMode (INMD)
- Bausch Health Companies (BHC)
- Cutera (CUTR)
- Cynosure
- Solta Medical
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does Apyx Medical Corp (APYX) do?
Apyx Medical is a surgical aesthetics company that develops and markets the Helium Plasma Platform Technology, including the Renuvion and AYON body contouring systems. The company's products are used by surgeons for various procedures, including fat removal, tissue contraction, and skin laxity treatment, in both cosmetic and hospital settings. Additionally, Apyx Medical leverages its expertise in unique waveforms through OEM manufacturing contracts with other medical device companies.
What sector is Apyx Medical Corp (APYX) in?
Apyx Medical Corp (APYX) is classified in the Health Care sector. Its industry is surgical aesthetics / medical devices. It trades on NASDAQ.
Who are Apyx Medical Corp's (APYX) competitors?
Notable peers of Apyx Medical Corp (APYX) include InMode, Bausch Health Companies, Cutera, Cynosure and Solta Medical. This peer set is informational only — not financial advice.
Is Apyx Medical Corp (APYX) overbought or oversold right now?
Apyx Medical Corp (APYX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 38, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on APYX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.